New Formulations for Oral, Nasal, Transdermal and Rectal Delivery of Cannabinoids

Touitou Elka, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Categories	Cannabinoid Administration, Formulation, Drug Delivery, Novel Carriers, Transdermal Formulation, Nasal Formulation, Oral formulation
Development Stage	In-vivo proof of concept
Patent Status	Several patent applications – new technologies for various routes of administration
Market	Improved effect of Cannabinoids which are administrated via different routes is a real need and has increasing demand

Background

There is a need for cannabinoids based products for treatment via various ways of administration (Nasal, Oral, Transdermal and Rectal), that are efficient and safe and show prolonged effective action.
Currently, cannabinoids are administrated in capsules or sublingual spray and the drug has only short action (a peak effect up to 4 hours with a median T max up to 2.5 hours).
Cannabinoids are very lipophilic molecules. Hence, in order to bring them to a molecular state (dissolved)-- solvents like vegetable oils, glycols (propylene glycol) and ethanol are used.
We have designed innovative cannabinoid formulations along the main routes of drug administration (dermal, nasal, oral and rectal) for treatment of various ailments: pain, neurological diseases, sleep, appetite, mood, anxiety, rheumatic arthritis, inflammatory diseases, and stress.

Highlights

Our new platform technologies for cannabinoids do not require oils or chemical solvents.
Eco-friendly preparation process with no need of high heating or use of solvents.
The inactive ingredients used in this new dosage form are approved for pharmaceutical use.
The technology is adequate for various cannabinoids: CBD, THC, iso-THC, CBG, CBC, CBN, CBE, CBL, CBT and their mixtures or for plant extracts.
In-vivo proof of concept

Our Innovation

Innovative formulations and compositions for design and development of new cannabinoid products for treatment of a wide range of diseases.

Key Features

Innovative transdermal, nasal, oral and rectal technologies for the development of new efficient products of cannabinoids (CBD, THC, others) for treatment of various diseases
IP
Excipients approved for pharmaceutical use
Eco-friendly processes
Experiments in a pain using an animal model that adminestered cannabinoids in the new oral formulation show a very efficient and prolonged antinociceptive effect.

Development Milestones

Seeking investment in new company or industrial collaboration for product development and clinical studies

Patent Status

Published CN108366962; WO 2019/016814